Merck’s Isentress in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1

Merck announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor Isentress (raltegravir) tablets in combination therapy in previously untreated adult HIV-1-infected patients.
MarketWatch